TY  - JOUR
T1  - Comparative Analysis of Intravitreal Ranibizumab versus Laser Therapy for Retinopathy of Prematurity
A1  - Ahmed Elabbasy
A1  - Mona Abdelbaky
A1  - Hassan Al-Shehri
A1  - Ilene Padua
A1  - Ahmed Hamed
A1  - Aladdin Kashlan
A1  - Abdullah Alrobaie
A1  - Abdulrahman Albarqi
A1  - Ammar Aldawalibi
A1  - Amer Ammari
A1  - Fawaz Kashlan
JF  - Archives of Pharmacy Practice
JO  - Arch Pharm Pract
SN  - 2320-5210
Y1  - 2022
VL  - 13
IS  - 2
DO  - 10.51847/6vtXeVdItu
SP  - 30
EP  - 36
N2  - The therapeutic effects of intravitreal Ranibizumab injection (IVR) and the efficacy of laser photocoagulation for the treatment of retinopathy of prematurity (ROP) are compared. The screening criteria for ROP were infants born with less than 32 weeks gestational period and/or weighed less than 1500 grams or unstable clinical course. After ethical approval from the Institutional Review Board, this retrospective study was conducted. The study considered 1315 infants and an observation was made that 36/42 (85.7%) eyes showed regression of ROP in the IVR group whereas 27/27 (100%) eyes that were treated with laser therapy showed regression of ROP (p=0.09). A considerable discrepancy in habituation of ROP in both groups with 12 eyes (28.6%) has been noted which is showing recurrence of ROP in the IVR group compared to 1 eye (3.7%) in the Laser group (P=0.01. In terms of anisometropia and refractive error, both groups made no notable difference. Squint was found remarkably higher in the laser group (29.6%) than in the IVR group (4.8%) (P=0.01). It was found that treating ROP eyes with laser treatment leads to greater improvement in infants than when treated by IVR. Moreover, a significant recurrence of ROP was discovered after IVR treatment in comparison with the laser treatment. 
UR  - https://archivepp.com/article/comparative-analysis-of-intravitreal-ranibizumab-versus-laser-therapy-for-retinopathy-of-prematurity-qgp0zj6asbbau5h
ER  -